trametinib india

Trametinib (Trametinib) is an oral, small molecule, selective, non-competitive inhibitor of adenosine triphosphate MEK2 and MEK2 (also known as MAP2K1 and MAP2K2) activation and kinase activity. It is understood that there is currently no Indian version of the generic version of Trametinib on the market, and the original version of Trametinib may be sold in India and other regions.

The U.S. Food and Drug Administration (FDA) approved trametinib as a single agent for the treatment of BRAF V600E or BRAF V600K mutation-positive unresectable or metastatic melanoma, and the FDA accelerated approval of trametinib and dabrafenib (a BRAF inhibitor) in combination for the same indication. Currently, trametinib is approved for monotherapy and combination therapy in metastatic tumors; however, it is more commonly used in combination therapy due to improved efficacy. It is worth noting that trametinib and dabrafenib are also approved for metastatic non-small cell lung cancer, anaplastic thyroid cancer, and are also approved for adjuvant treatment of melanoma.

The original drug of Trametinib has been launched in China and is included in the scope of medical insurance, but it may only be available to patients who meet the indications. The price of 2 mg*30 tablets is more than RMB 10,000. The original drug of Trametinib sold overseas, with the price of 2 mg*30 tablets, is more than RMB 7,000 (the price may fluctuate due to exchange rates). There are also generic trametinib drugs produced in other countries overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of a 2mg*30 tablet of a generic drug produced by a Laos pharmaceutical factory is more than 2,000 yuan (the price may fluctuate due to the exchange rate).